<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-1092</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МНЕНИЕ ПО ПРОБЛЕМЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPINION ON A PROBLEM</subject></subj-group></article-categories><title-group><article-title>Приверженность терапии статинами</article-title><trans-title-group xml:lang="en"><trans-title>Statin therapy compliance</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загидуллин</surname><given-names>Н. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagidullin</surname><given-names>N. Sh.</given-names></name></name-alternatives><email xlink:type="simple">nau36@ufanet.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загидуллин</surname><given-names>Ш. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagidullin</surname><given-names>Sh. Z.</given-names></name></name-alternatives><email xlink:type="simple">nau36@ufanet.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет, г. Уфа</institution></aff><aff xml:lang="en"><institution>Bashkir State Medical University. Ufa</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>20</day><month>02</month><year>2008</year></pub-date><volume>7</volume><issue>1</issue><fpage>107</fpage><lpage>111</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Загидуллин Н.Ш., Загидуллин Ш.З., 2008</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="ru">Загидуллин Н.Ш., Загидуллин Ш.З.</copyright-holder><copyright-holder xml:lang="en">Zagidullin N.S., Zagidullin S.Z.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/1092">https://cardiovascular.elpub.ru/jour/article/view/1092</self-uri><abstract><p>В последнее время показана высокая эффективность постоянного приема статинов не только при гиперлипидемиях, но и при различных формах ишемической болезни сердца, а также у лиц с высоким кардиоваскулярным риском. Низкая приверженность лечению значительно ограничивает эффективность данной группы препаратов. Знание факторов, обуславливающих низкую приверженность, позволяет предвидеть степень отношения больных к лечению, планировать тактику мониторирования терапии и обучения пациентов. Выбор эффективного статина, такого как аторвастатин, способствует более быстрому достижению целевых уровней липидов, обеспечивая хорошую приверженность пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Recently, high effectiveness of long-term statin therapy has been demonstrated not only for hyperlipidemias, but also for various forms of coronary heart disease and high cardiovascular risk. Low therapy compliance restricts statins’ effectiveness substantially. Awareness of the factors determining low compliance facilitates prediction of patients’ attitude towards treatment, as well as planning of therapy monitoring and patient education. Choosing an effective statin, e.g., atorvastatin, gives an opportunity to achieve target lipid levels faster and provides adequate treatment compliance.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>дислипидемия</kwd><kwd>лечение</kwd><kwd>приверженность</kwd><kwd>статины</kwd><kwd>аторвастатин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>dislipidemia</kwd><kwd>treatment</kwd><kwd>compliance</kwd><kwd>atorvastatin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Scandinavian Simvasthathin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvasthatin Survival Study (4S). Lancet 1994; 344: 1349–57.</mixed-citation><mixed-citation xml:lang="en">Scandinavian Simvasthathin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvasthatin Survival Study (4S). Lancet 1994; 344: 1349–57.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">The CARE Study Group (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335: 1001–9.</mixed-citation><mixed-citation xml:lang="en">The CARE Study Group (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335: 1001–9.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">The LIPID Study Group. Long term effectiveness and safety of pravastatine in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379–87.</mixed-citation><mixed-citation xml:lang="en">The LIPID Study Group. Long term effectiveness and safety of pravastatine in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379–87.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22.</mixed-citation><mixed-citation xml:lang="en">Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tamargo J, Caballero R, Gomez R, et al. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacology and Therapeutics 2007; 114: 107–26.</mixed-citation><mixed-citation xml:lang="en">Tamargo J, Caballero R, Gomez R, et al. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacology and Therapeutics 2007; 114: 107–26.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Abraha I, Montedori A, Stracci F, et al. Statin compliance in the Umbrian population. Eur J Pharmacol 2003; 59: 659–61.</mixed-citation><mixed-citation xml:lang="en">Abraha I, Montedori A, Stracci F, et al. Statin compliance in the Umbrian population. Eur J Pharmacol 2003; 59: 659–61.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mann DM, Allegrante JP, Natarajan S, et al. Predictors of Adherence to Statins for Primary Prevention. Cardiovasc Drugs Ther 2007; 21: 311–6.</mixed-citation><mixed-citation xml:lang="en">Mann DM, Allegrante JP, Natarajan S, et al. Predictors of Adherence to Statins for Primary Prevention. Cardiovasc Drugs Ther 2007; 21: 311–6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kaplan RC, Bhalodkar NC, Brown EJ, et al. Race, ethnicity, and sociocultural characteristics predict noncompliance with lipidlowering medications. Prev Med 2004; 39(6): 1249–55.</mixed-citation><mixed-citation xml:lang="en">Kaplan RC, Bhalodkar NC, Brown EJ, et al. Race, ethnicity, and sociocultural characteristics predict noncompliance with lipidlowering medications. Prev Med 2004; 39(6): 1249–55.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yilmaz MB, Biyikoglu SF, Guray Y, et al. Level of Awareness of on-Treatment Patients About Prescribed Statins. Am J Manag Care 2005; 11: 670–4.</mixed-citation><mixed-citation xml:lang="en">Yilmaz MB, Biyikoglu SF, Guray Y, et al. Level of Awareness of on-Treatment Patients About Prescribed Statins. Am J Manag Care 2005; 11: 670–4.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Thiebaud P, Patel BV, Pharm D, et al. The effect of Switching on Compliance and Persistance: The Case of of Statin Treatment. Am J Manag Care 2005; 11: 670–4.</mixed-citation><mixed-citation xml:lang="en">Thiebaud P, Patel BV, Pharm D, et al. The effect of Switching on Compliance and Persistance: The Case of of Statin Treatment. Am J Manag Care 2005; 11: 670–4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Blackburn DF, Pharm D, Dobson R, et al. Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy. Pharmacotherapy 2005; 25(8): 1035–43.</mixed-citation><mixed-citation xml:lang="en">Blackburn DF, Pharm D, Dobson R, et al. Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy. Pharmacotherapy 2005; 25(8): 1035–43.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta6blockers and angiotensin6converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005; 21(6): 485–8.</mixed-citation><mixed-citation xml:lang="en">Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta6blockers and angiotensin6converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005; 21(6): 485–8.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Benner JS, Glynn RJ, Mogun H, et al. Long6term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–61.</mixed-citation><mixed-citation xml:lang="en">Benner JS, Glynn RJ, Mogun H, et al. Long6term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–61.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229–33.</mixed-citation><mixed-citation xml:lang="en">Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229–33.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gotto AM, Grundy SM. Lowering LDL Cholesterol. Circulation 1999; 99: e4.</mixed-citation><mixed-citation xml:lang="en">Gotto AM, Grundy SM. Lowering LDL Cholesterol. Circulation 1999; 99: e4.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Водяницкая Н.А., Абдуева Ф.М., Гудилин Т.Е., Дановская Е.В. Полугодовая приверженность к лечению больных, перенесших острый коронарный синдром без элевации сегмента ST. http://www.rql.kiev.ua/cardio_j/2007/2/vodyanitskaya.htm</mixed-citation><mixed-citation xml:lang="en">Водяницкая Н.А., Абдуева Ф.М., Гудилин Т.Е., Дановская Е.В. Полугодовая приверженность к лечению больных, перенесших острый коронарный синдром без элевации сегмента ST. http://www.rql.kiev.ua/cardio_j/2007/2/vodyanitskaya.htm</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Riesen WF, Darioli R, Noll G. Lipid6lowering therapy strategies for improvning comliance. Curr Med Res Opin 2004; 20(2): 165–79.</mixed-citation><mixed-citation xml:lang="en">Riesen WF, Darioli R, Noll G. Lipid6lowering therapy strategies for improvning comliance. Curr Med Res Opin 2004; 20(2): 165–79.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Marquez CE, Marinez C, et al. Therapeutic comliance in dyslipidemias. A trial of the efficacy of health education. Aten Primaria 1998; 22: 79–84.</mixed-citation><mixed-citation xml:lang="en">Marquez CE, Marinez C, et al. Therapeutic comliance in dyslipidemias. A trial of the efficacy of health education. Aten Primaria 1998; 22: 79–84.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Schwed A, Fallab CI, Burnier M, et al. Electronic momnitoring of compliance to lipidlowering therapy to clinical practice. J Clin Pharmacol 1999; 39: 402–9.</mixed-citation><mixed-citation xml:lang="en">Schwed A, Fallab CI, Burnier M, et al. Electronic momnitoring of compliance to lipidlowering therapy to clinical practice. J Clin Pharmacol 1999; 39: 402–9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000; 20: 410–6.</mixed-citation><mixed-citation xml:lang="en">Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000; 20: 410–6.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jones PH, Davidson MH, Stein EA, et al. for STELLAR study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.</mixed-citation><mixed-citation xml:lang="en">Jones PH, Davidson MH, Stein EA, et al. for STELLAR study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
